|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori-infected animal models are extremely suitable for the investigation of gastric carcinogenesis显示文摘Although various animal models have been developed to clarify gastric carcinogenesis, apparent mechanism of gastric cancer was not clarified in recent years. Since the recognition of the pathogenicity of Helicobacter pylori (Hpylori), several animal models with Hpylori infection have been developed to confirm the association between Hpylori and gastric cancer. Nonhuman primate and rodent models were suitable for this study. Japanese monkey model revealed atrophic gastritis and p53mutation after long-term infection of Hpylori. Mongolian gerbil model showed the development of gastric carcinoma with H pylori infection alone, as well as with combination of chemical carcinogens, such as N-methylN-nitrosourea and N-methyl-N-nitro-N'-nitrosoguanidine.The histopathological changes of these animal models after Hpylori inoculation are closely similar to those in human beings with Hpylori infection. Eradication therapy attenuated the development of gastric cancer in Hpyloriinfected Mongolian gerbil. Although several features of animal models differ from those seen in human beings,these experimental models provide a starting point for further studies to clarify the mechanism of gastric carcinogenesis as a result of Hpylori infection and assist the planning of eradication therapy to prevent gastric carcinoma. | Masaaki Kodama Kazunari Murakami Ryugo Sato Tadayoshi Okimoto Akira Nishizono Toshio Fujioka | 2005 | World Journal of Gastroenterology2005，11，45： | 19 |
| 2 | Expression of mutant type-p53 products in H pylori-associated chronic gastritis显示文摘AIM:To investigate the mutation of p 53 immuno-histochemically in non-tumorous gastric mucosa with H pylori infection before and after H pylori eradication therapy.METHODS:53 subjects(36 male,17 female,mean age ± SEM,57.1 ± 12.1)undergoing endoscopic examination were included in this study.42 of 53 patients were H pylori-positive,and 11 were H pylori-negative.All H pylori-positive patients had successful eradication therapy.Biopsy specimens were taken from five points of the stomach,as recommended by the updated Sydney system.Immunohistochemical studies were performed by using primary antibodies against p53(DO-7 and PAb240).RESULTS:p53(DO-7 and PAb240)immunoreactivity was shown in the neck region of the gastric pits,however,quite a few cells were found to be immunopositive for p 53(PAb240)in the H pylori-infected gastric mucosa.The proportion of patients immunopositive for p 53(PAb240)was significantly reduced 6 mo after eradication [28/42(66.7%)to 6/42(14.3%)](P < 0.05),while the biopsies taken from H pylori-negative patients showed no immunoreactivity for p53(PAb240).p53(PAb240)-positive patients were divided into two groups by the number of positive cells detected:one with more than six positive cells per 10 gastric pits(group A,n = 12),and the other with less than five positive cells per 10 gastric pits(group B,n = 30).Atrophy scores in group A were significant higher than those in group B at the greater curvature of the antrum(group A:2.00 ± 0.14 vs group B:1.40 ± 0.15,P = 0.012),the lesser curvature of the corpus(group A:2.00 ± 0.21 vs group B:1.07 ± 0.23,P = 0.017),and the greater curvature of the corpus(group A:1.20 ± 0.30vs group B:0.47 ± 0.21,P = 0.031).Group A showed significant higher intestinal metaplasia scores than group B only at the lesser curvature of the antrum(group A:2.10 ± 0.41 vs group B:1.12 ± 0.29,P = 0.035).CONCLUSION:H pylori-associated chronic gastritis expressed the mutant-type p53,which was significantly associated with more severe atrophic and metaplastic changes.H pylori eradication led to a significant reduction in the expression of the mutant-type p53.It is considered that H pylori-infected chronic gastritis is associated with a genetic instability that leads to gastric carcinogenesis,and H pylori eradication may prevent gastric cancer. | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Koichiro Watanabe Toshio Fujioka | 2007 | World Journal of Gastroenterology2007，13，10： | 13 |
| 3 | 天然气超声速处理技术显示文摘传统的天然气分离处理设备造价高、安全性差,且对环境有污染。本文介绍一种设计新颖、结构简捷紧凑和工作可靠的天然气超声速分离处理技术,分析讨论了该项技术的优点,并用实例证实了该技术在天然气工艺处理中应用的或行性和发展前途。 | Dr.Fred Okimoto 梁书苓 范建敏 | 2003 | 国外油田工程2003，19，3： | 8 |
| 4 | Aspirin-induced small bowel injuries and the preventive effect of rebamipide显示文摘AIM:To evaluate the influence of taking low-dose aspirin for 4 wk on small intestinal complications and to examine the preventive effect of rebamipide.METHODS:This study was conducted as a single-center,randomized,double-blind,cross-over,placebo-controlled study.Eleven healthy male subjects were enrolled.Each subject underwent video capsule endos-copy after 1 and 4 wk of taking aspirin and omepra-zole,along with either rebamipide or placebo therapy.The primary endpoint was to evaluate small bowel damage in healthy subjects before and after taking low-dose aspirin for 4 wk.RESULTS:The number of subjects with mucosal breaks(defined as multiple erosions and/or ulcers)were 1 at 1 wk and 1 at 4 wk on the jejunum,and 6 at 1 wk(P = 0.0061)and 7 at 4 wk on the ileum(P =0.0019).Rebamipide significantly prevented mucosal breaks on the ileum compared with the placebo group(P = 0.0173 at 1 wk and P = 0.0266 at 4 wk).CONCLUSION:Longer-term,low-dose aspirin adminis-tration induced damage in the small bowel.Rebamipide prevented this damage,and may be a candidate drug for treating aspirin-induced small bowel complications. | Kazuhiro Mizukami Kazunari Murakami Takashi Abe Kunimitsu Inoue Masahiro Uchida Tadayoshi Okimoto Masaaki Kodama Toshio Fujioka | 2011 | World Journal of Gastroenterology2011，17，46： | 8 |
| 5 | Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test显示文摘AIM: To investigate the effects of proton pump inhibitor (PPI) treatment on stool antigen test using the TestMate pylori enzyme immunoassay. METHODS: This study assessed 28 patients [16 men and 12 women; mean age (63.1 ± 5.9) years; range, 25-84 years] who underwent stool antigen test and urea breath test (UBT) before and after PPI administration. RESULTS: Using the UBT as the standard, the sensitivity, specif icity and agreement of the stool antigen test in all 28 patients were 95.2%, 71.4%, and 89.3%, respectively, before PPI administration, and 88.9%, 90.9%, and 89.3%, respectively, after PPI treatment. Mean UBT values were 23.98% ± 5.33% before and 16.19% ± 4.75% after PPI treatment and, in 15 patients treated for ≥ 4 wk, were signif icantly lower after than before 4 wk of PPI treatment (12.58% ± 4.49% vs 24.53% ± 8.53%, P = 0.048). The mean optical density (A450/630) ratios on the stool antigen test were 1.16 ± 0.20 before and 1.17 ± 0.24 after PPI treatment (P = 0.989), and were 1.02 ± 0.26 and 0.69 ± 0.28, respectively, in the group treated for > 4 wk (P = 0.099). | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Yoshihiro Fukuda Tadashi Shimoyama Masumi Okuda Chieko Kato Intetsu Kobayashi Toshio Fujioka | 2012 | World Journal of Gastroenterology2012，18，1： | 7 |
| 6 | Two-week treatment with proton pump inhibitor is sufficient for healing post endoscopic submucosal dissection ulcers显示文摘AIM:To investigate the optimum period of treatment for post endoscopic submucosal dissection(ESD)ulcers.METHODS:Patients who underwent ESD for gastric cancer were randomized to two groups and treated with esomeprazole 20 mg per day for 4 wk(4W group)or 2 wk(2W group).At 4 wk after ESD,we measured the size of the artificial ulcers by endoscopy and determined the ulcer healing rate,compared with the size of the ESD specimens.This randomized controlled trial study was approved by our ethics committee and registered in the UMIN Clinical Trial Registry.RESULTS:A total of 60 consecutive patients were included in the study.All patients received rebamipide 300 mg per day for 4 wk.One patient in 2W group who showed bleeding within two weeks and received endoscopic treatment was excluded from further analysis.The numbers of patients with ulcers in the healing/scar stage in the 2W and 4W groups at 4 wk after ESD were 20/6 and 28/5,respectively,with no significant difference.The ulcer healing rate in the 2W and 4W groups were 96.1%[95%confidence interval(CI):94.6%-97.55]vs 94.8%(95%CI:92.6%-97.1%),respectively,with no statistical difference(UMIN000006951).CONCLUSION:Two-wk treatment with a proton pump inhibitor is as effective as four-week treatment for healing post ESD ulcers. | Makoto Arai Tomoaki Matsumura Kenichiro Okimoto Arata Oyamada Keiko Saito Shoko Minemura Daisuke Maruoka Takeshi Tanaka Tomoo Nakagawa Tatsuro Katsuno Osamu Yokosuka | 2014 | World Journal of Gastroenterology2014，20，43： | 6 |
| 7 | Chemical Composition of the Essential Oil of Mastic Gum and their Antibacterial Activity Against Drug-Resistant Helicobacter pylori显示文摘Mastic gum is derived from the tree named Pistacia lentiscus that is grown only in Island Hios of Greek.Since Mastic was first reported to kill Helicobacter pylori(H.pylori)in 1998,there has been no further study to elucidate which component of mastic specifically shows the antimicrobial activity against H.pylori.In this study,we examined which component of mastic gum was responsible for anti-H.pylori activity.We prepared the essential oil of mastic gum and identified 20 constituents by GC–MS analysis.Ten standard components were assayed for anti-H.pylori activity,and it clarified that a-terpineol and(E)-methyl isoeugenol showed the anti-H.pylori activity against four different H.pylori strains that were established from patients with gastritis,gastric ulcer and gastric cancer.These components could be useful to overcome the drug-resistance H.pylori growth in stomach. | Tomofumi Miyamoto Tadayoshi Okimoto Michihiko Kuwano | 2014 | Natural Products and Bioprospecting2014，4，4： | 4 |
| 8 | Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication显示文摘 | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Masahiro Uchida Takashi Abe Seiji Shiota Yoshifumi Nakagawa Kazuhiro Mizukami Toshio Fujioka | 2012 | Journal of Gastroenterology2012，，4： | 4 |
| 9 | Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy显示文摘 | K Murakami T Fujioka T Okimoto R Sato M Kodama M Nasu | 2002 | International Journal of Antimicrobial Agents2002，，1： | 2 |
| 10 | Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE) 7 m -β-CD as both a solubilizer and osmotic agent显示文摘 | Kazuto Okimoto Atsuo Ohike Rinta Ibuki Osamu Aoki Norio Ohnishi Roger A. Rajewski Valentino J. Stella Tetsumi Irie Kaneto Uekama | 1999 | Journal of Controlled Release1999，，2： | 2 |
| 11 | Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR显示文摘 | Bell DW Gore I Okimoto RA | 2005 | Nat Genet2005，37，12： | 1 |
| 12 | Development of cor- pus atrophic gastritis may be associated with Helicobacter pylo- ri-related idiopathic thrombocytopenic purpura显示文摘 | Sato R Murakami K Okimoto T | 2011 | J Gastroen- terol2011，46，8： | 1 |
| 13 | Guidelines for the manage- ment of Helicobacter pylori infection in Japan: current status and future prospects 显示文摘 | Fujioka T Yoshiiwa A Okimoto T | 2007 | J Gastroenterol2007，42，17： | 1 |
| 14 | Development of a highly efficient catalytic method for synthesis of vinyl ethers显示文摘 | OKIMOTO Y SAKAGUCHI S ISHII Y | 2002 | J Am Chem Soc2002，，8： | 1 |
| 15 | Engineered XcmⅠcassettecontaining vector for PCR-based phylogenetic analyses显示文摘 | ARANISHI F OKIMOTO T | 2004 | Journal of Genetics2004，83，1： | 1 |
| 16 | 显示文摘 | Tomioka Y Okuda T Okimoto Y | 2000 | Phys Rev B2000，61，1： | 1 |
| 17 | The mitochondrial genomes of two nematodes, Caenor- habditis elegans and Ascaris suum显示文摘 | Okimoto R Macfarlane J L Clary D O | 1992 | Genetics1992，130，： | 1 |
| 18 | Guidelines for the management of Helicobacter pylori infection in Japan:current status and future prospects显示文摘 | Fujioka T Yoshiiwa A Okimoto T | 2007 | J Gastroentero2007，42，17： | 1 |
| 19 | Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib 显示文摘 | Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW | 2004 | N Engl J Med2004，350，21： | 1 |
| 20 | Engineered Xcm I cassette-containing vector for PCR-based phylogenetic analyses显示文摘 | ARANISHI F OKIMOTO T | 2004 | J Genet2004，83，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员